Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

Sponsor
Yan Zhang, MD
Study ID
NCT06176729
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Diffuse Large B Cell Lymphoma

Eligibility Criteria

Sex
ALL
Age
70 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a prospective, single-arm, phase II study, and the purpose of this study is to evaluate the efficacy and safety of Pola-R2 regimen in newly diagnosed elderly diffuse large B cell lymphoma classified into un-fit or frail group by comprehensive geriatric assessment(CGA).

Key Dates

Start date
Oct 24, 2023
Status verified
Dec 2023
Primary completion
Oct 24, 2025
Completion
Oct 24, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental arm
    Pola-R2 regimen Drug: Polatuzumab Vedotin, Rituximab, Lenalidomide polatuzumab vedotin 1.8 mg/kg ivgtt D1, rituximab375 mg/m2 ivgtt D1, lenalidomide 25mg po D1-14, one cycle every 21 days

Primary Outcome Measure

complete remission rate [ Time Frame: evaluated every 3 months，up to 24 months ]

Central Contacts

Related Studies